Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/13/2003WO2003092733A1 Chemically activated carboxypolysaccharides and uses
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092730A1 Hydroxycitric acid salt composition and method of making
11/13/2003WO2003092722A1 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF
11/13/2003WO2003092721A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes
11/13/2003WO2003092720A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003WO2003092717A1 Cancer immunotherapy
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092713A1 7-hydroxy chromones as potent antioxidants
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092706A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003WO2003092704A1 External preparation enhanced in systemic property of vidarabine
11/13/2003WO2003092703A1 Methods and compositions for inhibition or irritation by disaccharide and metal ions
11/13/2003WO2003092702A1 Compositions and methods for treating inflammatory connective tissue diseases
11/13/2003WO2003092701A2 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
11/13/2003WO2003092700A1 Inositol pyrophosphates, and methods of use thereof
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092697A1 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
11/13/2003WO2003092696A1 Method for decreasing capillary permeability in the retina
11/13/2003WO2003092694A1 Treatment of diabetes and diabetic complications with nhe-1 inhibitors
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092692A1 Therapeutic agent comprising lafutidine
11/13/2003WO2003092691A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092689A1 The treatment of pain with ifendropil
11/13/2003WO2003092688A2 Heterocyclic derivatives as opioid modulators
11/13/2003WO2003092687A1 Methods of modulating smooth muscle contractility
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092685A1 USE OF PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) IN THE DIAGNOSIS AND TREATMENT OF CHRONIC LUNG DISEASE AND OTHER PATHOLOGIES
11/13/2003WO2003092683A1 Epothilone derivative for the treatment of hepatoma and other cancer diseases
11/13/2003WO2003092682A1 Zonisamide use in obesity and eating disorders
11/13/2003WO2003092681A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003WO2003092680A1 New surfactant-based formulation containing triclabendazole
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092677A1 Trans-epicutaneous administration form for treating restless leg syndrome
11/13/2003WO2003092676A1 Compositions and methods for preventing abuse of orally administered medications
11/13/2003WO2003092675A1 Drugs for mitigating taxane-induced neurotoxicity
11/13/2003WO2003092674A1 Prenatal multivitamin/multimineral supplement
11/13/2003WO2003092673A1 Use of epa and dha in secondary prevention
11/13/2003WO2003092672A1 Method of inhibiting rejection of transplanted material
11/13/2003WO2003092671A1 Method of inhibiting angiogenesis
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003092669A2 Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
11/13/2003WO2003092668A1 Use of agmatine for topical application
11/13/2003WO2003092667A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003WO2003092666A1 Calcium-containing tissue strengthening agents and use thereof
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092659A1 Oral dosage forms comprising fenofibrate
11/13/2003WO2003092655A2 Use of active ingredient mixtures with azelaic acids and glycyrrhetic acids as anti-acne agents
11/13/2003WO2003092654A1 Formulations limiting spread of pulmonary infections
11/13/2003WO2003092652A1 Warming and nonirritating anhydrous lubricant compositions
11/13/2003WO2003092651A1 Warming and nonirritating lubricant compositions
11/13/2003WO2003092650A1 Warming and nonirritating lubricant antifungal gel compositions
11/13/2003WO2003092649A2 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
11/13/2003WO2003092648A1 Methods and dosage forms for controlled delivery of oxycodone
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092645A2 Cosmetic composition comprising monosaccharides or polysaccharides____________________________________
11/13/2003WO2003092644A2 Mouth hygiene product containing sugar esters and sugar ethers as antimicrobial active ingredients
11/13/2003WO2003092641A1 Topical glycopyrrolate product
11/13/2003WO2003092633A2 Diffusion-controlled dosage form and method of fabrication including three dimensional printing
11/13/2003WO2003092629A2 Methods of simultaneously treating mucositis and fungal infection
11/13/2003WO2003092628A2 High-quality lipids and methods for producing by enzymatic liberation from biomass
11/13/2003WO2003092626A2 Carvedilol pharmasolve solvate
11/13/2003WO2003092625A2 Carvedilol formulations
11/13/2003WO2003092622A2 Carvedilol monocitrate monohydrate
11/13/2003WO2003092621A2 Composition and method for dermatological treatment
11/13/2003WO2003092617A2 Combinations for the treatment of inflammatory skin disorders
11/13/2003WO2003092616A2 Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
11/13/2003WO2003092614A2 Lipid removal from the body
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092606A2 Cholinesterase inhibitors to prevent injuries caused by chemicals
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092596A2 TREATING ECZEMA WITH A COMBINATION OF ISOTONIC SALINE OCEANè AND MAST CELL STABILIZERS
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092592A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
11/13/2003WO2003092591A2 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
11/13/2003WO2003092590A2 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
11/13/2003WO2003092589A2 Salt solution for colon cleansing
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092586A2 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003092584A2 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
11/13/2003WO2003092583A2 Methods and compositions for treating ectoparasite infestation
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003092578A2 Further syntheses of cyproterone acetate
11/13/2003WO2003092478A2 Methods for treating neuronal disorders
11/13/2003WO2003092468A2 Biomatrix structural containment and fixation systems and methods of use thereof
11/13/2003WO2003092379A1 Fatty acid containing teat dip
11/13/2003WO2003092374A2 Pesticidal heterocycles
11/13/2003WO2003082864A3 Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
11/13/2003WO2003080056A3 Fine particle size pioglitazone
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003072090A3 Use of tyrosine kinase inhibitors for treating cns disorders
11/13/2003WO2003068955A3 Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003066034A3 Use of compounds and compositions derived form olives for protecting cells against dna damage
11/13/2003WO2003066001A3 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
11/13/2003WO2003063822A3 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
11/13/2003WO2003063821A3 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
1 ... 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 5292 5293 5294 5295 ... 7860